Document Detail


Therapeutic use of the high-density lipoprotein protein and peptides.
MedLine Citation:
PMID:  16503760     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the novel techniques of coronary evaluation. A number of reports have examined the potential therapeutic properties of the synthetic HDLs prepared by complexing recombinant apolipoprotein (apo) A-I(Milano), a variant form of native apoA-I, with phospholipids. The availability of synthetic HDL complexes containing recombinant apoA-I(Milano) has opened up a new era of therapeutic management for coronary disease. HDL formulations of recombinant apoA-I(Milano)-phospholipid complexes have clearly shown rapid regression of a focal carotid atheroma as well as powerful protection from myocardial infarction in a rabbit model. In a pilot study, ETC-216 showed a significant reduction in coronary plaque burden after five weekly treatments, assessed by intravascular ultrasound in patients with acute coronary syndrome. Other therapeutic options of HDL therapy have recently became available.
Authors:
Marta Marchesi; Cesare R Sirtori
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-28     Completed Date:  2006-04-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  227-41     Citation Subset:  IM    
Affiliation:
Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy. Marta.Marchesi@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apolipoprotein A-I / therapeutic use
Arteriosclerosis / drug therapy,  pathology
Coronary Disease / drug therapy,  pathology
Humans
Lipoproteins, HDL / therapeutic use*
Peptides / therapeutic use*
Phosphatidylcholines / therapeutic use
Chemical
Reg. No./Substance:
0/Apolipoprotein A-I; 0/ETC216; 0/Lipoproteins, HDL; 0/Peptides; 0/Phosphatidylcholines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent developments in antibacterial drug discovery: microbe-derived natural products--from collecti...
Next Document:  Recent findings concerning thiazolidinediones in the treatment of diabetes.